FARMINGDALE, N.Y., May 2, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications has announced their attendance at the American Physical Therapy Association's (APTA) Combined Sections Meeting (CSM), which was held in New Orleans, LA, February 10-12, 2011. Misonix exhibited and presented its SonicOne® Ultrasonic Wound Cleansing and Debridement System to many of the more than 5,000 clinicians in attendance. In addition, the SonicOne was demonstrated during the Wound Debridement Skills Pre-Conference Course on February 9, 2011.
As part of the educational program a clinical poster was presented on February 12, 2011 that focused on the clinical effectiveness of the SonicOne when used to treat chronic wounds. Frank Aviles, PT, CWS, WCC, FAACWS, Director of Therapy for a leading long term acute care facility in Natchitoches, LA, was the author and presenter of the material. Three separate clinical cases were followed from patient admission to wound closure. In two of the cases, the initial clinical plan included amputation. However, using a SonicOne debridement protocol to remove non-viable tissue allowed the establishment of a well-granulated wound bed, which contributed to healing, and resulted in both patients retaining their limbs and functional mobility.
The SonicOne is an innovative ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is pleased to demonstrate its commitment to the rapidly expanding wound care market by supporting important educational programs like APTA-CSM," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Our wound care product platform, we believe, makes an important contribution to improving patient outcomes and we are pleased when data is presented by clinical experts that support our investment in wound care research and development."About APTA: APTA, which has a specialty section for advanced wound care, is a national professional organization representing more than 71,000 members. Its goal is to foster advancements in physical therapy practice, research, and education. The CSM is a unique conference that focuses on programming designed by all 18 of APTA's specialty sections. About Misonix: Misonix, Inc. (NASDAQ: MSON) designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com. With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.